Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Dobbs

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
British Journal of Cancer|April 3, 1999
Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancerK J O'Byrne, N Dobbs, D J Propper, et al.
Cancer Research|August 27, 1999
The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patientsP Thavasu, D Propper, A McDonald, et al.
Population Health Management|September 16, 2021
Redesigning Kidney Disease Care to Improve Value DeliveryTitte R Srinivas, Justin J Coran, Esther J Thatcher, et al.
European Journal of Cancer (Oxford, England : 1990)|August 4, 2004
Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinomaD I Jodrell, T R J Evans, W Steward, et al.
British Journal of Cancer|May 27, 2004
Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancerP H Jones, K Christodoulos, N Dobbs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2001
A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesisJ P Braybrooke, K J O'Byrne, D J Propper, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
British Journal of Cancer|April 3, 1999
Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancerK J O'Byrne, N Dobbs, D J Propper, et al.
Cancer Research|August 27, 1999
The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patientsP Thavasu, D Propper, A McDonald, et al.
Population Health Management|September 16, 2021
Redesigning Kidney Disease Care to Improve Value DeliveryTitte R Srinivas, Justin J Coran, Esther J Thatcher, et al.
European Journal of Cancer (Oxford, England : 1990)|August 4, 2004
Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinomaD I Jodrell, T R J Evans, W Steward, et al.
British Journal of Cancer|May 27, 2004
Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancerP H Jones, K Christodoulos, N Dobbs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2001
A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesisJ P Braybrooke, K J O'Byrne, D J Propper, et al.
Pageof 2